Fight against COVID-19
Diagnostic antibody & antigen
Services
- Custom AAV Production
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Supports
SOCAIL MEDIA
Human ACE2 overexpression stable HEK293T cell lines
Validation Data Post Download
Cat No.: GM-SC-293T‐hACE2-01
Order informatioin
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GM-SC-293T‐hACE2-01 | Vial | 4288 | ||
| Shipping Cost: | 960.00 | |||
| Total: | ||||
Validation of hACE2 overexpression stable HEK293T cell lines (Cat. GM-SC-293T‐hACE2-01)
Figure. ACE2 mRNA level Validation in hACE2 overexpression stable HEK293T cell lines: Cat. GM‐SC‐293T‐hACE2‐01 (A) and the cell lines were tested as Mycoplasma free (B).
SARS-CoV-2 Pseudotyped virus
GeneMedi’s SARS-CoV-2 Pseudovirus-Luciferase (Cat.GM-2019nCoV-PSV01) is recombinant pseudotyped lentiviral particles containing SARS-CoV-2 spike protein to mimic SARS-CoV-2 (2019nCoV) cell infection and cell entry4.
The SARS-CoV-2 pseudovirus particles encode firefly luciferase and RFP in their lentiviral vector genome. The firefly luciferase and RFP gene will be strongly expressed after the SARS-CoV-2 pseudovirus entry into ACE2-expressing cells. Actually, 293T-hACE2(human ACE2 overexpression stable HEK293T cell lines) is normally used as effector cell.
GM-2019nCoV-PSV01 is a powerful tool for SARS-CoV-2 related vaccine efficacy evaluation, neutralizing antibodies, peptides blockers competitors neutralization assay, and tissue-specific infection determination.
GeneMedi SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry
Data Post Download
 |
 |
 |
|
Figure. GeneMedi-SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry validation with fluorescence(A), Luciferase activity (B) and FACS (C) after 72 hours of HEK293T infection. hACE2 significantly enhanced the infection efficiency of the SARS-CoV-2 PSV. |
GeneMedi offers:
1. SARS-CoV-2 Pseudotyped virus packaging and production (Cat.GM-2019nCoV-PSV01)
| Catalot Number | Size(T,Test, formalized in 96 well, one test per well) |
Price(In USD) |
| GM-2019nCoV-PSV01-1 | 100T | $3,840.00 |
| GM-2019nCoV-PSV01-1 | 200T | $5,440.00 |
| GM-2019nCoV-PSV01-2 | 1000T | $21,760.00 |
| GM-2019nCoV-PSV01-2 | 5000T | $87,040.00 |
| For larger scale | Click for inquiry. | Click for inquiry. |
| Shipping & handling fee | $760.00 | |
2. Effector cells: human ACE2 overexpression stable HEK293T cell lines, Catalot Number: GM-SC-293T-hACE2-01
Click here FOR INQUIRY
3. SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay Service for evaluating:
1) Neutralizing antibodies
2) Peptides blockers(peptide inhibitors)
3) Types of Vaccines3(by testing immunized serum from mouse, NHP etc.)
4) Compounds targeting Spike induced cell-fusion.
SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay
In the Pseudovirus Based Neutralization Assay (PBNA), the inhibition of viral entry into cells by neutralizing antibodies is correlated to the decreased levels of firefly luciferase signals in the ACE2 expression cells (hACE2-HEK293T).
1) Neutralizing antibodies
2) Peptides blockers (peptide inhibitors)
3) Types of Vaccines3
4) Compounds targeting Spike induced cell-fusion.
Related products
References
1 XiaolongCai. An Insight of comparison between COVID-19 (2019-nCoV) and SARS-CoV in pathology and pathogenesis. Preprint, doi:10.31219/osf.io/hw34x (2020, paper of GeneMedi).
2 Jean K. Millet1, Tiffany Tang3, Lakshmi Nathan3, Javier A. Jaimes4, Hung-Lun Hsu3,5, & Susan Daniel3, G. R. W. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp, doi:10.3791/59010 (2019).
3 HuajunBai, X., XiaolongCai. Vaccines And Advanced Vaccines: -A landscape for advanced vaccine technology against infectious disease, COVID-19 and tumor. Preprint, doi:10.31219/osf.io/ypgx4 (2020, paper of GeneMedi).
4 Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 9, 680-686, doi:10.1080/22221751.2020.1743767 (2020).
